Clinical Trial Update: Efficacy of Telbivudine in Blacks/African Americans and Hispanics/Latinos With Compensated Chronic Hepatitis B During 52 Weeks [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluating telbivudine in Black/African American and Hispanic/Latino patients with compensated chronic hepatitis B was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• Telbivudine (telbivudine)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Compensated Chronic Hepatitis B | Phase 4 | Status: WITHDRAWN